2024-10-04 2025-10-31 2025-10-31 false 15997619 Unigiro Limited 58290Other software publishing iso4217:GBP xbrli:pure 159976192024-10-04 159976192025-10-31 159976192024-10-04 2025-10-31 15997619bus:SmallEntities2024-10-04 2025-10-31 15997619bus:AuditExempt-NoAccountantsReport2024-10-04 2025-10-31 15997619bus:FullAccounts2024-10-04 2025-10-31 15997619core:WithinOneYear2025-10-31 15997619core:AfterOneYear2025-10-31 15997619core:WithinOneYear2024-10-04 2025-10-31 15997619core:AfterOneYear2024-10-04 2025-10-31 15997619core:CurrentFinancialInstruments2025-10-31 15997619core:Non-currentFinancialInstruments2025-10-31 15997619core:CurrentFinancialInstruments2024-10-04 2025-10-31 15997619core:Non-currentFinancialInstruments2024-10-04 2025-10-31 15997619core:LandBuildings2024-10-04 2025-10-31 15997619core:FurnitureFittings2024-10-04 2025-10-31 15997619core:OfficeEquipment2024-10-04 2025-10-31 15997619core:Vehicles2024-10-04 2025-10-31 15997619core:PlantMachinery2024-10-04 2025-10-31 15997619core:OtherPropertyPlantEquipment2024-10-04 2025-10-31 15997619core:LandBuildings2025-10-31 15997619core:PlantMachinery2025-10-31 15997619core:Vehicles2025-10-31 15997619core:FurnitureFittings2025-10-31 15997619core:OfficeEquipment2025-10-31 15997619core:OtherPropertyPlantEquipment2025-10-31 15997619core:Right-of-useAssets2024-10-04 2025-10-31 15997619core:Right-of-useAssets2025-10-31 15997619core:Goodwill2024-10-04 2025-10-31 15997619core:PatentsTrademarksLicencesConcessionsSimilar2024-10-04 2025-10-31 15997619core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-10-04 2025-10-31 15997619core:OtherResidualIntangibleAssets2024-10-04 2025-10-31 15997619core:Goodwill2025-10-31 15997619core:DevelopmentCostsCapitalisedDevelopmentExpenditure2025-10-31 15997619core:PatentsTrademarksLicencesConcessionsSimilar2025-10-31 15997619core:OtherResidualIntangibleAssets2025-10-31 15997619dpl:CostSales2024-10-04 2025-10-31 15997619dpl:AdministrativeExpenses2024-10-04 2025-10-31 15997619dpl:DistributionCosts2024-10-04 2025-10-3115997619core:ShareCapital2025-10-31 15997619core:SharePremium2025-10-31 15997619core:RevaluationReserve2025-10-31 15997619core:OtherReservesSubtotal2025-10-31 15997619core:ShareCapitalPreferenceShares2025-10-31 15997619core:CapitalRedemptionReserve2025-10-31 15997619core:OtherCapitalReserve2025-10-31 15997619core:RetainedEarningsAccumulatedLosses2025-10-3115997619core:ShareCapital2024-10-04 2025-10-31 15997619core:SharePremium2024-10-04 2025-10-31 15997619core:RevaluationReserve2024-10-04 2025-10-31 15997619core:OtherReservesSubtotal2024-10-04 2025-10-31 15997619core:RetainedEarningsAccumulatedLosses2024-10-04 2025-10-311599761912024-10-04 2025-10-31 1599761922024-10-04 2025-10-3115997619core:ShareCapital12024-10-04 2025-10-31 15997619core:ShareCapital22024-10-04 2025-10-3115997619core:SharePremium12024-10-04 2025-10-31 15997619core:SharePremium22024-10-04 2025-10-3115997619core:RevaluationReserve12024-10-04 2025-10-31 15997619core:RevaluationReserve22024-10-04 2025-10-3115997619core:RetainedEarningsAccumulatedLosses12024-10-04 2025-10-31 15997619core:RetainedEarningsAccumulatedLosses22024-10-04 2025-10-311599761912024-10-04 2025-10-3115997619core:Non-currentFinancialInstrumentscore:CostValuation2024-10-04 15997619core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:TransfersIntoOrOutInvestmentsIncreaseDecreaseInInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:CostValuation2025-10-3115997619core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2024-10-04 15997619core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:FurtherSpecificIncreaseDecreaseInProvisionsForImpairmentInvestments1ComponentCorrespondingTotal2025-10-31 15997619core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-10-31 15997619core:Non-currentFinancialInstrumentscore:ProvisionsForImpairmentInvestments2025-10-3115997619core:Non-currentFinancialInstruments2025-10-31 15997619core:Non-currentFinancialInstruments2024-10-0315997619bus:Director12024-10-04 2025-10-3115997619bus:PrivateLimitedCompanyLtd2024-10-04 2025-10-31
Unigiro Limited
Unaudited Financial Statements
for the period ended 31 October 2025
Company registration number 15997619
(England and Wales)

Company Information

For the period 4 October 2024 to 31 October 2025
Director Lupini, Andrea, Dr

Registered office 124 City Road
London
EC1V 2NX

Registered number 15997619

Accountant Accounts & Tax services

Statement of Financial Position

As at 31 October 2025
Notes
2025
£
£
Fixed assets
Intangible assets
4
7,562
7,562
Current assets
Debtors
5
1,702
1,702
Creditors
Amounts falling due within one year
6
(699)
(699)
Net current assets (liabilities)
1,003
Total assets less current liabilities
8,565
Net assets (liabilities)
8,565
Capital and reserves
Called up share capital
7
8,570
Other reserves
9
4
Profit and loss account
(9)
Total equity
8,565

The company is a private company limited by shares and registered in England and Wales. It was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime.
The directors have chosen to not file a copy of the company's profit and loss account under section 444 (5A) of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 2 July 2026 and are signed on its behalf by:

Lupini, Andrea, Dr
Lupini, Andrea, Dr
Director

Company registration number 15997619

Notes to the Financial Statements

For the period 4 October 2024 to 31 October 2025

1. Statutory information

The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The financial statements are presented in sterling and this is the functional currency of the company.

2. Accounting policies

2.1. Basis of preparation

The financial statements have been prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

The financial statements have been prepared under the historical cost convention in accordance with the Companies Act 2006.

2.2. Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis of accounting in preparing its financial statements to represent a fair valuation based on available tangible and intangible resources.

2.3. Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the rendering of services and from the sale of goods.


Revenue from the rendering of services is recognised by reference to the stage of completion of the contract and when the customer accepted the Terms and paid for the service. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.


Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.


2.4. Foreign currencies

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

2.5. Government grants R&D expenditure credits

The company accounts for government grants using the performance model in accordance with Section 24 of FRS 102.

Government grants are recognised at the fair value of the amount received or receivable when there is reasonable assurance that the company will comply with the conditions attaching to the grant and that the grant will be received. Grants subject to specified performance conditions are recognised in income when those conditions are satisfied. Grants that do not impose specified future performance conditions are recognised in income when the grant becomes receivable. Where grant proceeds are received before the conditions for recognition in income have been satisfied, the amount received is recognised as a liability until those conditions are met.


R&D expenditure credits are recognised gross within other operating income when there is reasonable assurance that the qualifying conditions of the applicable R&D scheme have been met, the amount can be measured reliably and the credit will be received. Any related corporation tax effect is recognised separately within taxation. Amounts receivable at the reporting date are included within debtors and separately identified where material.

2.6. Deferred tax

Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

2.7. Intangible assets

The company applies FRS 102 Section 18 to its intangible assets. Qualifying development expenditure is presented as intangible assets under development until the asset is available for its intended use. Intangible assets available for its intended use are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.

Development costs

Unless when classified as intangible assets under development, the capitalised development costs are stated at cost less accumulated amortisation and accumulated impairment losses (cost model). Amortisation is recognised using the straight-line basis and results in the carrying amount being expensed in profit or loss over the estimated useful life.

Research and development

All research and development costs are expensed in the fiscal year unless qualify under the merged R&D tax relief scheme. Costs related to the development of products are capitalised when they meet the criteria stated in FRS 102, Section 18 Intangible assets other than Goodwill. All other development expenditure is recognised as an expense in the period in which it is incurred.

2.8. Financial instruments

Election and recognition

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.


Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

3. Employees

The average number of employees during the year was 0.

4. Intangible assets

Other intangibles
Total
£
£
Cost
Additions
7,562
7,562
At 31 October 2025
7,562
7,562
Amortisation and impairment
At 31 October 2025
-
-
Net book value
At 31 October 2025
7,562
7,562

At the reporting date, the balance classified within Other intangible assets comprises qualifying development expenditure capitalised in respect of assets under development, in accordance with the company's accounting policy. Where applicable, the related expenditure has also been considered for relief under the UK merged Research and Development Expenditure Credit scheme.

5. Debtors

2025
£
Other debtors
586
Total due within one year
586
Other debtors
1,116
Total due after one year
1,116
Total
1,702

At the reporting date, debtors included Cash and cash equivalents comprise cash at bank and in hand and are stated at their nominal value and an amount receivable from HM Revenue & Customs in respect of the company's claim under the merged Research and Development Expenditure Credit scheme and required Additional Information Form that was properly prepared. The amount of gross R&D expenditure credits as corporation Tax receivable is £ 1.116,40 as it is expected to be recovered or offset against the company's corporation tax liabilities.



6. Creditors due within one year

2025
£
Trade creditors
743
Taxation and social security
(44)
Total
699

At the reporting date there is an account payable for £743.00 which is expected to be settled withing the next 12 months.

And, the VAT amount refundable for £44 that are substantiated by checks received from HMRC.

7. Share capital

2025
£
Allotted, called up and fully paid
Allotted, called up and fully paid ordinary shares
8,570
Allotted, uncalled nil-paid shares
141,430
Total
150,000

The company has allotted 150000 ordinary shares of £1 each and called-up share capital for total 8570 ordinary shares fully paid-up.

The remaining 141430 ordinary shares were issued nil-paid, and the aggregate nominal amount of £141430 remained uncalled at the reporting date.

8. Share premium account

The share premium account includes the premium on issue of equity ordinary shares, net of any issue costs for an amount of £ 3.70.

9. Other reserves

At the reporting date, the following is included within other reserves: